HD is an inherited neurodegenerative disorder which causes uncontrolled movement, and eventually cognitive decline and emotional disturbances.
Working in the Ferguson lab where Ribeiro was a postdoctoral trainee, the scientists crossed two mouse models. One was a mouse which doesn’t have glutamate receptors –they’ve been knocked out genetically, and the other is a HD mouse model which over-expresses mutant human Huntington protein. They found if they deleted mGluR5, they lost the pathology of Huntington’s in the neurons, and they saw improvements in motor behaviour which normally would be impaired in these mice.
“What we found was, if we block mGluR5, which is the glutamate receptor we’re interested in, the mice become hyper locomotive so they become able to move better than wild type mice suggesting glutamate receptors might be a good target for treating movement disorders such as Parkinson’s disease. So that was a bit of a surprise that came out in the study, and we can show that genetically and pharmaceutically,” says Ferguson who holds a Canada Research Chair in Molecular Neurobiology. “And the good thing is, there are mGluR5 antagonists now in stage three clinical trials for diseases such as Fragile X, so it is quite possible these drugs will be available for patients in the future.”
Video of Ferguson explaining his research can be found at http://youtu.be/uTkzu0r79IA
The research was funded by the Canadian Institutes of Health Research.
Media contact: Kathy Wallis, Media Relations Officer, Schulich School of Medicine & Dentistry, Western University, 519-661-2111 ext. 81136, Kathy.firstname.lastname@example.org